Abstract
Introduction: As a reason for hearing disorders by patients with thalassemic syndromes arc underlined the ototoxicity of deferoxamine in the therapy of the thalassemia. Objective: The aim of the study is to establish the presence of hearing disorders by patients with thalassemic syndromes under regular haemotransfusions and chelating therapy. Study design: Multicentre prospective research - ENT Clinic, Paediatric Clinic, Therapeutic Clinic, Medicine Faculty, Stara Zagora; 6-th Therapeutic Department, District Hospital "Prof. S. Kirkovich", Stara Zagora; Sector of Thalassemia, Paediatric Hospital, Sofia; Sector of Thalassemia, National Centre of Transfusiology, Sofia. Material and Methods: 63 patients with beta-thalassemia under regular hacmotransfusions and chelating therapy were examinated. For the assessment of the hearing function were used otoacoustic emissions, audiometry and brainstem evoked potentials. Results: By 15 patients with thalassemic syndromes (23.81 %) were registreted abnormal audiogram's - neurosensorial hearing disorder. By 4 of them the hearing disorder was combining. Disscusion: Our results by assessment of the hearing function arc not so different of the results in the studies of many authors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
